Paper39736624
Transcriptome analysis reveals the anticancer effects of fenbendazole on ovarian cancer: an in vitro and in vivo study.
Wang X and 10 others. BMC Cancer, 2024. Cited by 2 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Download JSON
Cite this record
ConductScience Library. Transcriptome analysis reveals the anticancer effects of fenbendazole on ovarian cancer: an in vitro and in vivo study. Papers, record 39736624. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39736624
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Transcriptome analysis reveals the anticancer effects of fenbendazole on ovarian cancer: an in vitro and in vivo study.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Fenbendazole | Major topic |
| Ovarian Neoplasms | Major topic |
| Apoptosis | Major topic |
| Gene Expression Profiling | Major topic |
| Xenograft Model Antitumor Assays | Major topic |
| Cell Proliferation | Major topic |
| Female | |
| Humans | |
| Animals | |
| Mice | |
| Cell Line, Tumor | |
| Gene Expression Regulation, Neoplastic | |
| Antineoplastic Agents | |
| Transcriptome | |
| Mice, Nude |
Source PubMed
Grants5
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| XDYC-MY-2022-0056 | "Xingdian Talent Support Plan" for Outstanding Doctors in Yunnan Province | PubMed | ||
| 202201AY070001-138 | the Basic research in Yunnan Province (Kunming Medical University Joint Project) | PubMed | ||
| 202201AY070001-162 | the Basic research in Yunnan Province (Kunming Medical University Joint Project) | PubMed | ||
| 202305AS350020 | The innovative research team of Yunnan Province | PubMed | ||
| YNWR-MY-2019-039 | Yunnan Province "Ten Thousand People Plan" | PubMed |
Source PubMed
References41
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 39,084,502 | Anti-cancer effects of nitazoxanide in epithelial ovarian cancer in-vitro and in-vivo. | Chem Biol Interact | 2024 | https://conductscience.org/library/papers/39084502 | PubMed |
| 2 | 19,238,148 | Cell cycle, CDKs and cancer: a changing paradigm. | Nat Rev Cancer | 2009 | https://conductscience.org/library/papers/19238148 | PubMed |
| 3 | 36,977,989 | p20BAP31 induces cell apoptosis via both AIF caspase-independent and the ROS/JNK mitochondrial pathway in colorectal cancer. | Cell Mol Biol Lett | 2023 | https://conductscience.org/library/papers/36977989 | PubMed |
| 4 | 32,203,277 | Targeting apoptosis in cancer therapy. | Nat Rev Clin Oncol | 2020 | https://conductscience.org/library/papers/32203277 | PubMed |
| 5 | 26,491,220 | Targeting the Mitotic Catastrophe Signaling Pathway in Cancer. | Mediators Inflamm | 2015 | https://conductscience.org/library/papers/26491220 | PubMed |
| 6 | 30,093,705 | Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways. | Sci Rep | 2018 | https://conductscience.org/library/papers/30093705 | PubMed |
| 7 | 37,625,527 | Perspectives and mechanisms for targeting mitotic catastrophe in cancer treatment. | Biochim Biophys Acta Rev Cancer | 2023 | https://conductscience.org/library/papers/37625527 | PubMed |
| 8 | 38,230,766 | Cancer statistics, 2024. | CA Cancer J Clin | 2024 | https://conductscience.org/library/papers/38230766 | PubMed |
| 9 | 20,214,619 | Mechanisms of drug-induced mitotic catastrophe in cancer cells. | Curr Pharm Des | 2010 | https://conductscience.org/library/papers/20214619 | PubMed |
| 10 | 35,409,093 | Necroptosis as a Novel Facet of Mitotic Catastrophe. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/35409093 | PubMed |
| 11 | 24,078,660 | Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. | Ann Oncol | 2013 | https://conductscience.org/library/papers/24078660 | PubMed |
| 12 | 35,849,264 | Mechanisms of cancer cell death induction by paclitaxel: an updated review. | Apoptosis | 2022 | https://conductscience.org/library/papers/35849264 | PubMed |
| 13 | 24,910,927 | Wee1 and Cdc25 control morphogenesis, virulence and multistress tolerance of Beauveria bassiana by balancing cell cycle-required cyclin-dependent kinase 1 activity. | Environ Microbiol | 2015 | https://conductscience.org/library/papers/24910927 | PubMed |
| 14 | 35,569,513 | Fenbendazole and its synthetic analog interfere with HeLa cells' proliferation and energy metabolism via inducing oxidative stress and modulating MEK3/6-p38-MAPK pathway. | Chem Biol Interact | 2022 | https://conductscience.org/library/papers/35569513 | PubMed |
| 15 | 12,234,300 | A shift in the Bax/Bcl-2 balance may activate caspase-3 and modulate apoptosis in experimental glomerulonephritis. | Kidney Int | 2002 | https://conductscience.org/library/papers/12234300 | PubMed |
| 16 | 36,039,738 | Anti-cancer effects of fenbendazole on 5-fluorouracil-resistant colorectal cancer cells. | Korean J Physiol Pharmacol | 2022 | https://conductscience.org/library/papers/36039738 | PubMed |
| 17 | 34,886,882 | A link between mitotic defects and mitotic catastrophe: detection and cell fate. | Biol Direct | 2021 | https://conductscience.org/library/papers/34886882 | PubMed |
| 18 | 35,740,967 | Growth-Suppressive and Apoptosis-Inducing Effects of Tetrandrine in SW872 Human Malignant Liposarcoma Cells via Activation of Caspase-9, Down-Regulation of XIAP and STAT-3, and ER Stress. | Biomolecules | 2022 | https://conductscience.org/library/papers/35740967 | PubMed |
| 19 | 16,675,948 | Apoptosis regulation in tetraploid cancer cells. | EMBO J | 2006 | https://conductscience.org/library/papers/16675948 | PubMed |
| 20 | 22,094,106 | Albendazole sensitizes cancer cells to ionizing radiation. | Radiat Oncol | 2011 | https://conductscience.org/library/papers/22094106 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42,924,578 | Erythropoietin beyond red blood cells: Systemic and oncological functions (Review). | Mol Med Rep | 2026 | https://conductscience.org/library/papers/42924578 |
Source PubMed
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39736624
GET https://conductscience.org/api/papers/v1/39736624/references?page=2